Skip to main content
. 2017 Dec 22;5(1):ofx275. doi: 10.1093/ofid/ofx275

Table 2.

Distribution of Biomarker Concentrations in Participants With Available Baseline Data According to Adherence Category and Fold Difference in Available Baseline Inflammatory and Coagulopathy Biomarker Plasma Concentrations in Suboptimally Adherent, Virologically Suppressed PLWH on ART Enrolled in SMART

Biomarker Unadjusted Analysis Adjusted Analysisa
100% Adherence Suboptimal Adherence Fold Higher Level Compared With 100% Adherenceb 95% CI P Value Fold Higher Level Compared With 100% Adherenceb 95% CI P Value
No. Mean (SD) No. Mean (SD)
IL-6, pg/mL 2372 2.60 (6.93) 391 2.93 (4.53) 1.16 1.06–1.26 .0005 1.09 1.01–1.18 .02
D-dimer, μg/mL 2382 0.30 (0.59) 394 0.38 (1.06) 1.17 1.05–1.29 .002 1.11 1.01–1.22 .03
hsCRP, μg/mL 2397 3.72 (7.08) 396 4.27 (7.51) 1.07 0.94–1.23 .31 1.04 0.91–1.17 .58

Abbreviations: ART, antiretroviral therapy; CI, confidence interval; hsCRP, high-sensitivity C-reactive protein; IL-6, interleukin 6; PLWH, people living with HIV.

a

Models were adjusted for covariates including age, race, gender, body mass index, time on ART, HIV exposure group, baseline viral load, baseline and nadir CD4+ T-cells, hepatitis B or C co-infection, smoking, and regimen type.

b

100% adherence defined as no report of any missed doses for any drug in the preceding 7-day period.